Although genomics is destined to revolutionize clinical medicine, to date its beneficial effects have been somewhat muted. The promise and perils of genomics are emblemized by one of its flagship applications, namely the diagnosis of familial adenomatosis polyposis (FAP). FAP is an autosomal dominant syndrome characterized by numerous colonic adenomas which, without recognition and intervention, generally result in development of early-onset colorectal cancer, along with higher risks of several other malignancies (eg, duodenum, pancreas, thyroid, brain). Approximately 2 decades ago, it was discovered that germline mutations of the adenomatous polyposis coli (APC) tumor suppressor gene with concomitant overactivity in the Wingless-type mouse mammary tumor virus integration site (WNT) signaling cascade were responsible for most (approximately 80%-90%) FAP cases.1,2 More recently, a small subset of FAP cases were attributed to biallelic germline mutations of the base excision–repair gene mutY homologue (MUTYH)3.
Roy HK, Khandekar JD. APC Gene Testing for Familial Adenomatosis Polyposis. JAMA. 2012;308(5):514–515. doi:10.1001/jama.2012.9516
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: